iTeos Therapeutics Reports Positive Phase 2 Cancer Trial Results
PremiumCompany AnnouncementsiTeos Therapeutics Reports Positive Phase 2 Cancer Trial Results
2M ago
iTeos Therapeutics announces follow-up interim data from GALAXIES Lung-201
Premium
The Fly
iTeos Therapeutics announces follow-up interim data from GALAXIES Lung-201
2M ago
iTeos Therapeutics initiated with an Overweight at Wells Fargo
Premium
The Fly
iTeos Therapeutics initiated with an Overweight at Wells Fargo
3M ago
iTeos Therapeutics (NASDAQ:ITOS): Harnessing the Power of Immunotherapy
PremiumMarket NewsiTeos Therapeutics (NASDAQ:ITOS): Harnessing the Power of Immunotherapy
6M ago
iTeos Therapeutics price target raised to $46 from $44 at H.C. Wainwright
Premium
The Fly
iTeos Therapeutics price target raised to $46 from $44 at H.C. Wainwright
6M ago
iTeos Therapeutics to sell 1.14M shares at $17.50 in registered direct offering
Premium
The Fly
iTeos Therapeutics to sell 1.14M shares at $17.50 in registered direct offering
6M ago
iTeos Therapeutics reports Q4 EPS (85c), consensus ($1.03)
PremiumThe FlyiTeos Therapeutics reports Q4 EPS (85c), consensus ($1.03)
8M ago
iTeos Therapeutics appoints DeSimone to board of directors
Premium
The Fly
iTeos Therapeutics appoints DeSimone to board of directors
8M ago
iTeos Therapeutics announces 2024 strategic priorities, anticipated milestones
Premium
The Fly
iTeos Therapeutics announces 2024 strategic priorities, anticipated milestones
10M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100